Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Institutional Ownership: 11.21% (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688319 Chengdu Olymvax Biopharmaceuticals Inc SHSE:688319
76 GF Score
Price ¥28.23
GF Value ¥22.47
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Chengdu Olymvax Biopharmaceuticals Institutional Ownership?

Chengdu Olymvax Biopharmaceuticals SHSE:688319 -1.33% 76 Institutional Ownership is 11.21% as of Sep. 05, 2026. GuruFocus rates SHSE:688319 with a GF Score™ of 76/100 and a GF Value™ of ¥22.47 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Chengdu Olymvax Biopharmaceuticals's institutional ownership is 11.21%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Chengdu Olymvax Biopharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Chengdu Olymvax Biopharmaceuticals's Float Percentage Of Total Shares Outstanding is 0.00%.

Chengdu Olymvax Biopharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Chengdu Olymvax Biopharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chengdu Olymvax Biopharmaceuticals Institutional Ownership Chart

Chengdu Olymvax Biopharmaceuticals Historical Data

The historical data trend for Chengdu Olymvax Biopharmaceuticals can be seen below:

2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31 2026-08-31
Institutional Ownership 12.07 12.98 12.98 12.98 12.97 12.96 12.96 13.20 13.20 11.21
SHSE:688319
76GF Score
Chengdu Olymvax Biopharmaceuticals Inc SHSE:688319
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chengdu Olymvax Biopharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 11.21% mean?
Chengdu Olymvax Biopharmaceuticals (SHSE:688319) has a Institutional Ownership of 11.21% as of Sep. 05, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Chengdu Olymvax Biopharmaceuticals and its competitors.
Is Chengdu Olymvax Biopharmaceuticals' Institutional Ownership too high?
Chengdu Olymvax Biopharmaceuticals' current Institutional Ownership is 11.21%. Overall, Chengdu Olymvax Biopharmaceuticals has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Olymvax Biopharmaceuticals' Institutional Ownership compare to VRTX and REGN?
Chengdu Olymvax Biopharmaceuticals' Institutional Ownership of 11.21% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Chengdu Olymvax Biopharmaceuticals and its competitors. Chengdu Olymvax Biopharmaceuticals's current Institutional Ownership is 11.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Olymvax Biopharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals (SHSE:688319) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥22.47, compared to a current price of ¥28.23 — trading 25.6% above its estimated fair value. The current Institutional Ownership is 11.21%. Chengdu Olymvax Biopharmaceuticals' overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Chengdu Olymvax Biopharmaceuticals (SHSE:688319), the current Institutional Ownership is 11.21% as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Overvalued in 2026?

Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals stock appears to be overvalued. The current stock price of ¥28.23 is trading 25.6% above its estimated GF Value™ of ¥22.47. GuruFocus considers Chengdu Olymvax Biopharmaceuticals to be Modestly Overvalued.

Key valuation signals for SHSE:688319:

  • Institutional Ownership: 11.21%
  • GF Value™: ¥22.47 vs. price of ¥28.23 (25.6% above fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688319 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chengdu Olymvax Biopharmaceuticals Business Description

Address 99 Tianxin Road, High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.
76GF Score

Get the complete analysis for SHSE:688319

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥28.23
Price
¥22.47
GF Value